Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating yesterday.
Graig Suvannavejh has given his Buy rating due to a combination of factors that suggest Vigil Neuroscience Inc. remains a promising investment despite recent market reactions. The key aspect influencing this decision is the belief that the recent sell-off of VIGL shares was an overreaction to negative Phase 2 data from Alector’s TREM2-targeting antibody in Alzheimer’s disease, which is not directly comparable to Vigil’s approach.
Vigil’s VG-3927, a small molecule candidate, exhibits several potential advantages over Alector’s AL002, such as better blood-brain barrier penetration and lower risk of ARIA, due to its receptor agonist properties. Moreover, Vigil has conducted extensive testing that predicted AL002’s failure, reinforcing confidence in their own development. These strategic differences, coupled with an attractive valuation of VIGL shares, support Suvannavejh’s optimism and recommendation to capitalize on potential stock weaknesses.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vigil Neuroscience Inc (VIGL) Company Description:
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
